HC Wainwright Lifts Earnings Estimates for Pharming Group

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Equities research analysts at HC Wainwright increased their Q2 2026 earnings estimates for Pharming Group in a research note issued on Thursday, May 7th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $0.30 for the quarter, up from their previous estimate of $0.12. HC Wainwright currently has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.38 per share. HC Wainwright also issued estimates for Pharming Group’s Q3 2026 earnings at $0.30 EPS, Q4 2026 earnings at $0.20 EPS, FY2026 earnings at $0.70 EPS and FY2027 earnings at $0.80 EPS.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.12). The business had revenue of $72.45 million for the quarter, compared to analysts’ expectations of $92.06 million. Pharming Group had a return on equity of 4.64% and a net margin of 3.30%.

Several other research firms also recently commented on PHAR. Canaccord Genuity Group initiated coverage on shares of Pharming Group in a research note on Friday, April 10th. They set a “buy” rating and a $37.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $41.00 target price (down from $42.00) on shares of Pharming Group in a research note on Friday, March 13th. Wall Street Zen downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings raised shares of Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, April 27th. Finally, Zacks Research raised shares of Pharming Group from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Pharming Group currently has an average rating of “Moderate Buy” and a consensus target price of $38.33.

Pharming Group Trading Down 1.0%

PHAR stock opened at $12.85 on Tuesday. The company has a market capitalization of $907.40 million, a PE ratio of 80.31 and a beta of 0.04. Pharming Group has a one year low of $8.69 and a one year high of $21.34. The company’s 50 day moving average price is $16.13 and its two-hundred day moving average price is $16.55. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.06 and a current ratio of 2.63.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC bought a new position in Pharming Group in the 2nd quarter worth $32,000. SmartHarvest Portfolios LLC purchased a new stake in shares of Pharming Group in the 4th quarter worth about $224,000. Millennium Management LLC purchased a new stake in shares of Pharming Group in the 4th quarter worth about $360,000. Finally, NewEdge Advisors LLC lifted its position in shares of Pharming Group by 11,310.3% in the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after purchasing an additional 28,615 shares during the period. 0.03% of the stock is currently owned by institutional investors.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.